This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the ...

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

Key Takeaways Bausch + Lomb is discussing a possible sale that would separate it from its parent company, Bausch Health ...

Financial writers report on private equity interest in a potential takeover of Bausch & Lomb, with firms like Blackstone and ...

Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company is considering selling itself. Of note, Bausch + Lomb is the eye-care ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

Larry Biegelsen, an analyst from Wells Fargo, assigned the Buy rating on Bausch + Lomb Corporation (BLCO – Research Report). The ...